Scottish Researchers Link Whole-Body Scans to Cellular Detail in New Cancer Imaging Method
Researchers at the University of Glasgow have developed a preclinical imaging system that combines PET scans, bioluminescence, and fluorescence to track cancer from the whole body down to individual cells. This technology allows scientists to identify significant lesions and examine the cellular environment, including immune cells and blood vessels, to understand why tumors respond differently to treatments. While currently limited to mouse models, the method aims to improve the precision of cancer research and future therapies.
Key points
- The new imaging method integrates PET scans with bioluminescence and fluorescence to connect whole-body tumor locations with microscopic cellular details.
- Developed by Professor David Lewis and colleagues at the Cancer Research UK Scotland Institute, the system helps identify which lesions are most critical for treatment response.
- The technology allows researchers to label cancer cells, tracking their movement, growth, and interaction with the surrounding immune system and blood vessels.
- Currently, the method is preclinical and tested only in mice, specifically in liver and lung cancer models, but it may eventually apply to other fields like immunology and neuroscience.
- The approach addresses the limitation of current tools, where whole-body scans lack cellular detail and microscopy cannot track disease across the entire body.
Background
This development follows recent discussions on the limitations of elective whole-body MRI screenings, which experts warn often lead to unnecessary testing without improving survival. Additionally, it complements earlier findings on the non-uniform nature of aging at the cellular level, suggesting that understanding individual cell behavior is crucial for disease prevention and treatment. Recent studies on chemotherapy-induced mutations in pediatric cancers also highlight the need for precise monitoring of how treatments reshape tumor biology over time.
Why it matters
By bridging the gap between macroscopic body scans and microscopic cellular analysis, this technology could lead to more personalized cancer treatments. Understanding why specific tumors resist therapy while others respond could help in developing targeted interventions. Although not yet available for human patients, this preclinical tool offers a clearer map of cancer behavior, potentially reducing the trial-and-error approach in oncology and improving the efficiency of drug testing.
What to watch
Researchers will continue to refine the imaging method to better represent the underlying biology of cancer in preclinical models. The team plans to explore the application of this technology in other areas, including immunology and regenerative medicine, to further understand how diseases evolve and respond to interventions at both macro and micro levels.
Want the full story? Read the original reporting
Read on SciTechDaily